Hospital operator HCA Healthcare (NYSE: HCA) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 3.6% year on year to $19.85 billion. The company expects the full year’s revenue to be around $78.25 billion, close to analysts’ estimates. Its GAAP profit of $7.27 per share was 7% above analysts’ consensus estimates.

Is now the time to buy HCA? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

HCA Healthcare’s third quarter results modestly exceeded Wall Street’s expectations, driven by continued growth in demand for its hospital services and improvements in core cost management initiatives. CEO Samuel Hazen attributed the company’s performance to 22 consecutive quarters of volume growth, highlighting that “insured volumes grew faster in the quarter than in the first half of the year.” Management also pointed to an increase in revenue per adjusted admission for insured patients and incremental net benefits from Medicaid supplemental payment programs as key factors offsetting pressure from a rising uninsured patient population. CFO Michael Marks underscored that strong operating discipline led to essentially flat costs per equivalent admission versus the prior year, despite ongoing challenges in payer mix and elective surgical volumes.

Looking ahead, HCA’s leadership expects steady demand for services, with volume growth forecasted in line with historical trends. However, management cautioned that continued shifts in payer mix—specifically, more patients becoming uninsured after losing exchange coverage—will remain a significant headwind into next year. Hazen outlined that “fewer people will lose their coverage on the health insurance exchanges than we experienced in 2026,” but the impact on revenue mix will persist. The company’s ongoing enterprise-wide resiliency program and digital transformation initiatives are expected to drive future cost efficiencies. Management also highlighted the potential impact of pending federal policy changes and evolving Medicaid supplemental payment programs on profitability.

Key insights from management’s remarks

Management attributed the quarter’s performance to robust insured patient volumes, improvements in cost discipline, and incremental Medicaid program benefits, while acknowledging ongoing headwinds from payer mix and elective surgery trends.

• Insured volume growth: The company saw higher growth rates among insured patients, which partially offset ongoing declines in volumes from patients losing exchange coverage and becoming uninsured, a trend that continues to impact overall payer mix.
• Elective surgery softness: Outpatient and inpatient elective surgery volumes remained under pressure, with management citing both coverage losses and affordability challenges as primary factors. However, emergent surgical and trauma cases showed strength, and increased activity in other service lines, like cardiac and neonatal care, helped counterbalance the softness in elective procedures.
• Medicaid supplemental payment boost: HCA reported a $50 million net benefit from Medicaid supplemental payment programs in the quarter, largely due to a newly approved initiative in Virginia. Management expects these one-time state program benefits to be lower next year, as most catch-up payments have been realized.
• Enterprise resiliency program: The ongoing resiliency agenda—focused on cost optimization, asset utilization, and digital transformation—delivered solid cost containment results. CFO Michael Marks emphasized that “operating leverage from expected volume growth” and new shared service capabilities are now embedded in HCA’s operating model.
• Ambulatory network expansion: HCA continued to invest in ambulatory care, including urgent care and outpatient surgery centers. This network expansion, coupled with better patient coordination and higher hospital occupancy rates, is enabling the company to capture incremental demand and improve service accessibility.

Drivers of future performance

Management’s outlook highlights sustained demand, ongoing payer mix headwinds, and continued execution on cost and digital initiatives as central themes.

• Payer mix uncertainty persists: The shift of patients from exchange coverage to uninsured status is expected to remain a headwind, impacting revenue mix and profitability. Management anticipates some stabilization but does not expect a full recovery in elective surgical demand, as affordability and insurance coverage remain uncertain factors.
• Medicaid supplemental payment reset: One-time state Medicaid payments that benefited 2026 results are not expected to repeat, which will reduce incremental net benefits in 2027. This, combined with federal policy adjustments, adds complexity to forecasting future earnings.
• Cost discipline and digital transformation: The company’s enterprise-wide resiliency and digital initiatives are expected to drive ongoing cost efficiencies. Management is focused on expanding shared service platforms and leveraging technology to optimize labor, supply, and fixed costs, supporting margin stability despite reimbursement and payer mix pressures.

Catalysts in upcoming quarters

Looking forward, the StockStory team will be monitoring (1) the pace and sustainability of insured volume growth across key markets, (2) the company’s ability to manage ongoing shifts in payer mix and absorb lower Medicaid supplemental payments, and (3) whether digital transformation and resiliency initiatives deliver further cost efficiencies. We also see updates on surgery trends and policy changes as important markers.

HCA Healthcare currently trades at $470.77, up from $465.26 just before the earnings. Is there an opportunity in the stock? Find out in our full research report (it’s free).

High quality stocks for all market conditions

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.